Health

Opinion: Why the FDA should not approve an ineffective multicancer screening test

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/10/2026, 14:37:24 UTC.

Briefings

An opinion piece argues against FDA approval of a multicancer screening test due to a flawed randomized trial design. The evidence highlights a company's failure to meet a suboptimal surrogate endpoint in a trial of 140,000 participants, despite receiving approval. This approval is linked to the Medicare Multi-Cancer Early Detection Screening Coverage Act, which mandates coverage for such tests. The article suggests the FDA advisory panel may have overlooked the trial's methodological flaws, potentially leading to taxpayer-funded coverage for ineffective screening.

Key points

• A company failed to meet a suboptimal surrogate endpoint in a randomized trial involving 140,000 people.
• The FDA advisory panel recommended approval for this test despite the trial failure.

Context

The Medicare Multi-Cancer Early Detection Screening Coverage Act passed earlier this year mandates coverage for such tests, creating a potential conflict between the trial results and regulatory approval.

Limitations

The evidence is limited to the provided opinion text, which does not contain the full trial details, the specific failure metrics, or the exact reasons for the FDA panel's decision. The article does not provide the source link or further background on the trial's methodology.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/10/2026, 06:25:22 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiewiltmk6k47rk47ep2lnjkrvnm3jqymr7qgefviifc4fpg552zte